U.S. Markets close in 4 hrs 30 mins
  • S&P 500

    3,625.89
    +48.30 (+1.35%)
     
  • Dow 30

    30,001.91
    +410.64 (+1.39%)
     
  • Nasdaq

    11,990.73
    +110.10 (+0.93%)
     
  • Russell 2000

    1,848.32
    +30.03 (+1.65%)
     
  • Crude Oil

    45.12
    +2.06 (+4.78%)
     
  • Gold

    1,803.40
    -34.40 (-1.87%)
     
  • Silver

    23.26
    -0.37 (-1.58%)
     
  • EUR/USD

    1.1886
    +0.0041 (+0.3447%)
     
  • 10-Yr Bond

    0.8770
    +0.0200 (+2.33%)
     
  • Vix

    22.05
    -0.61 (-2.69%)
     
  • GBP/USD

    1.3354
    +0.0032 (+0.2417%)
     
  • USD/JPY

    104.6350
    +0.1470 (+0.1407%)
     
  • BTC-USD

    19,222.35
    +770.39 (+4.18%)
     
  • CMC Crypto 200

    382.10
    +12.35 (+3.34%)
     
  • FTSE 100

    6,421.76
    +87.92 (+1.39%)
     
  • Nikkei 225

    26,165.59
    +638.22 (+2.50%)
     

SHAREHOLDER ALERT: FLDM BMRN TCMD: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

·3 min read

NEW YORK, NY / ACCESSWIRE / October 30, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Fluidigm Corporation (NASDAQ:FLDM)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/fluidigm-corporation-loss-submission-form?prid=10608&wire=1
Lead Plaintiff Deadline: November 20, 2020
Class Period: February 7, 2019 - November 5, 2019

Allegations against FLDM include that: (1) Fluidigm was experiencing longer sales cycles; (2) as a result, Fluidigm's revenue was reasonably likely to decline; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form?prid=10608&wire=1
Lead Plaintiff Deadline: November 24, 2020
Class Period: February 28, 2020 - August 18, 2020

Allegations against BMRN include that: (i) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec, an investigational adenoassociated virus gene therapy, limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec's durability of effect; (ii) as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the Biologics License Application for valoctocogene roxaparvovec without additional data; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Tactile Systems Technology, Inc. (NASDAQ:TCMD)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/tactile-systems-technology-inc-loss-submission-form?prid=10608&wire=1
Lead Plaintiff Deadline: November 30, 2020
Class Period: May 7, 2018 - June 8, 2020

Allegations against TCMD include that: (1) while Tactile publicly touted a $4 plus billion or $5 plus billion market opportunity, in truth, the total addressable market for Tactile's pneumatic compression devices was materially smaller; (2) to induce sales growth and share gains, Tactile and/or its employees were engaged in illicit and illegal sales and marketing activities in violation of applicable federal and state rules and public payer regulations; (3) the foregoing illicit and illegal sales and marketing activities increased the risk of a Medicare audit of Tactile's claims and criminal and civil liability; (4) Tactile's revenues were in part the product of unlawful conduct and thus unsustainable; and that as a result of the foregoing, (5) Defendants' public statements, including Tactile's year-over-year revenue growth, the purported growth drivers, and the effectiveness of Tactile's internal controls over financial reporting were materially false and misleading at all relevant times.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong



View source version on accesswire.com:
https://www.accesswire.com/613670/SHAREHOLDER-ALERT-FLDM-BMRN-TCMD-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines